RxDoctor Payments Data

Lynn McClatchey

Women's Health · Spokane, WANPI 1811989940

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $1,100 of the $1,316 with a category attached, or 83.6%. 10 manufacturers reported payments, led by Astellas Pharma US Inc at 29.7% of the total. Reporting peaked in 2023 at $665 and has fallen 81.0% since, to $126 in 2024.

$1,316in general payments, 2019–2025

Across 66 payments — averaging $19.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$391
  • Sumitomo Pharma America, Inc.$283
  • Boston Scientific$146
  • Urovant Sciences Inc$128
  • AbbVie$105
  • 180 Medical, Inc.$91
  • plus $171 from 4 others

What the payments were for

  • Food & beverage$1,10084%
  • Education$21616%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,316 in reported general payments places this provider in the 85th percentile of 101 women's health providers in Washington.

See all women's health providers in Washington

Medicare billing

Part B allowed, 2024
$15,616
Medicare patients
165
Services billed
287

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron47$46,154
EstringEstradiol20$11,290
GemtesaVibegron13$10,838
Estradiol87$6,187
Tolterodine Tartrate ErTolterodine Tartrate23$2,875
Methenamine Hippurate17$1,266
Clobetasol Propionate28$1,059
Solifenacin Succinate34$932
Cephalexin33$310
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst16$197
Oxycodone Hcl17$36

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$391$46,15447 claims
PfizerEstring$69$11,29020 claims
Sumitomo Pharma America, Inc.Gemtesa$283$10,83813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 101 women's health providers in Washington.

Other women's health in Spokane

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →